View : 38 Download: 0

Assessment of Quality of Life and Safety in Postmenopausal Breast Cancer Patients Receiving Letrozole as an Early Adjuvant Treatment

Title
Assessment of Quality of Life and Safety in Postmenopausal Breast Cancer Patients Receiving Letrozole as an Early Adjuvant Treatment
Authors
Cho, Young UpGwak, Geum HeePark, Yong LaeKim, Sang WookHan, SehwanCho, Se HunKim, Lee SuMoon, Byung InJung, Sung HooLim, Chol WanKim, Sung YongPark, Ho YongSong, JeongyoonLee, Kwang ManPark, Sung HwanJeong, JoonPark, Hae LinKim, Sung WonKwak, Beom SeokKang, Sun HeeJung, YongsikLee, Soo JungLee, JuneyoungNoh, Woo ChulNam, Seok JinPark, Byeong-WooBae, Young TaeKang, Sung-SooParks, Heung KyuYoon, Jung-HanKim, Je Ryong
Ewha Authors
문병인
SCOPUS Author ID
문병인scopus
Issue Date
2018
Journal Title
JOURNAL OF BREAST CANCER
ISSN
1738-6756JCR Link2092-9900JCR Link
Citation
vol. 21, no. 2, pp. 182 - 189
Keywords
Breast neoplasmsLetrozoleQuality of lifeTreatment
Publisher
KOREAN BREAST CANCER SOC
Indexed
SCIE; SCOPUS; KCI WOS
Abstract
Purpose: There are few reports from Asian countries about the long-term results of aromatase inhibitor adjuvant treatment for breast cancer. This observational study aimed to evaluate the long-term effects of letrozole in postmenopausal Korean women with operable breast cancer. Methods: Self-reported quality of life (QoL) scores were serially assessed for 3 years during adjuvant letrozole treatment using the Korean version of the Functional Assessment of Cancer Therapy-Breast questionnaires (version 3). Changes in bone mineral density (BMD) and serum cholesterol levels were also examined. Results: All 897 patients received the documented informed consent form and completed a baseline questionnaire before treatment. Adjuvant chemotherapy was administered to 684 (76.3%) subjects, and 410 (45.7%) and 396 (44.1%) patients had stage I and II breast cancer, respectively. Each patient completed questionnaires at 3, 6, 12, 18, 24, 30, and 36 months after enrollment. Of 897 patients, 749 (83.5%) completed the study. The dropout rate was 16.5%. The serial trial outcome index, the sum of the physical and functional well-being subscales, increased gradually and significantly from baseline during letrozole treatment (p<0.001). The mean serum cholesterol level increased significantly from 199 to 205 after 36 months (p = 0.042). The mean BMD significantly decreased from -0.39 at baseline to -0.87 after 36 months (p<0.001). Conclusion: QoL gradually improved during letrozole treatment. BMD and serum cholesterol level changes were similar to those in Western countries, indicating that adjuvant letrozole treatment is well tolerated in Korean women, with minimal ethnic variation.
DOI
10.4048/jbc.2018.21.2.182
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE